1. Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval 
Eduardo Rodríguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla- Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramírez, María Moya- Arnao, Enric Carreras, Ildefonso Espigado-Tocino, José Antonio Pérez-Simón 
Biology of Blood and Marrow Transplantation 
Volume 25, Issue 1, Pages (January 2019)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Cumulative incidences of transplantation from the time of approval to proceed to transplant by (A) donor group allocation and (B) disease status at the time of transplantation approval. Early disease refers to CR1 after frontline chemotherapy or transplantation approval at diagnosis, while advanced disease includes CR1 after second or further line treatment, >CR1, PR, or refractory/relapsed (R/R) disease.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Cumulative incidences of failure to reach transplantation from the time of approval to proceed to transplant by donor group allocation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
Clinical outcomes from the time of transplant by donor type assignment: (A) OS, (B) LFS, (C) RI, (D) NRM, (E) grade II to IV aGVHD, and (F) cGVHD. Log-rank or Gray's p values are shown.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

5. Figure 4
Clinical outcomes from the time of transplant approval by donor type assignment. (A) OS, (B) LFS, and (C) RI. Log-rank or Gray's p values are shown.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions